SCHEMBL2093744

SCHEMBL2093744

O=C(O)c1c[nH]c2nc(N3CC(O)C3)c(F)cc2c1=O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM3 Q86V86 3/20 0.45
MAPKAPK3 Q16644 2/20 0.45
RPS6KB1 P23443 1/20 0.45
MATK P42679 1/20 0.45
DYRK1A Q13627 1/20 0.45
AURKB Q96GD4 1/20 0.45
FLT4 P35916 2/20 0.43
EPHA2 P29317 1/20 0.43
GSK3B P49841 1/20 0.43
RARB P10826 1/20 0.43
TBXAS1 P24557 1/20 0.43
SLC6A3 Q01959 1/20 0.43
DYRK3 O43781 1/20 0.43
SRPK1 Q96SB4 1/20 0.43
CSNK1G1 Q9HCP0 1/20 0.43
LMNA P02545 4/20 0.42
CYP2C9 P11712 3/20 0.42
ATP6V1B2 P21281 1/20 0.42
TBXA2R P21731 1/20 0.42
EDNRA P25101 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2092727 0.91 PIM3 (0.52) PIM3MAPKAPK3RPS6KB1MATKDYRK1A
SCHEMBL2093030 0.90 PIM3 (0.54) PIM3MAPKAPK3RPS6KB1MATKDYRK1A
SCHEMBL21679700 0.90 PIM3 (0.47) PIM3MAPKAPK3RPS6KB1MATKDYRK1A
SCHEMBL2094583 0.88 DPP4 (0.47) PIM3MAPKAPK3RPS6KB1MATKDYRK1A
SCHEMBL2095213 0.88 DPP4 (0.47) PIM3MAPKAPK3RPS6KB1MATKDYRK1A
SCHEMBL2097125 0.86 LMNA (0.48) PIM3MAPKAPK3RPS6KB1MATKDYRK1A
SCHEMBL2094951 0.86 LMNA (0.48) PIM3MAPKAPK3RPS6KB1MATKDYRK1A
SCHEMBL2092205 0.85 PIM3 (0.55) PIM3MAPKAPK3RPS6KB1MATKDYRK1A
SCHEMBL9535386 0.84 LMNA (0.60) PIM3MAPKAPK3RPS6KB1MATKDYRK1A
SCHEMBL2094065 0.84 PIM3 (0.66) PIM3MAPKAPK3RPS6KB1MATKDYRK1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030232818-A1 Antibacterial compounds ABBVIE INC. 2003-12-18 US claimed
US-8163769-B2 1,8-naphthyridine derivatives ABBOTT LABORATORIES (US) 2012-04-24 US disclosed
US-20030232818-A1 Antibacterial compounds ABBVIE INC. 2003-12-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030232818-A1 Antibacterial compounds PGLS, UGT1A1, CASP1 PIM3 3424/4885MAPKAPK3 2241/4885RPS6KB1 369/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.